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Background: Overweight and obesity are common among patients with Cushing’s syndrome (CS) and may persist
in some patients even after ostensibly curative surgery, contributing to cardiometabolic dysfunction and increased
cardiovascular risk. Mifepristone, a selective glucocorticoid receptor antagonist, was effective in controlling hyperglycemia
in a 24-week trial of adults (N = 50) with endogenous CS and associated type 2 diabetes mellitus/impaired
glucose tolerance or hypertension who had failed or were not candidates for surgery (SEISMIC, Study of the
Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing’s Syndrome). This analysis examines
long-term weight change among patients who received mifepristone in SEISMIC and enrolled in a long-term
safety extension (LTE) study.
Methods: Patients completing the 24-week SEISMIC study and subsequent 6-week off-drug safety evaluation
were invited to enroll in the LTE study. Mifepristone doses at the end of SEISMIC were the LTE starting doses.
Body weight measures were reviewed at baseline and week 24 of SEISMIC and at LTE month 6, 12, 18, 24, and
final visit (last observation collected during the LTE study).
Results: Of the 30 patients enrolled in the LTE, evaluable weight data were available for 29 (20/29 female; mean
age of 44.7 ± 11.2 years). These patients received mifepristone for a median of 29.2 months (range 8.4–41.9).
Mean ± SD weight from SEISMIC baseline to LTE final visit decreased by 10.3 ± 16.3 kg (mean 105.4 ± 34.3 kg to
95.1 ± 32.9 kg), a 9.3 % decrease from baseline weight (P = 0.0008). Of the 29 LTE patients, 18 (62.1 %) lost ≥5 %
of body weight by the end of the initial 24-week treatment period; this ≥5 % weight loss persisted in 83.3 %
(15/18) at LTE final visit. Ten patients (34.5 %) lost ≥10 % of initial body weight by week 24 of SEISMIC, which
persisted in 80 % at LTE final visit. No new safety signals were detected with long-term mifepristone use.
Conclusion: Clinically meaningful weight loss achieved during a 24-week study of mifepristone for CS persisted
for two additional years in patients who remained on therapy. Long-term treatment with mifepristone appears to
have a beneficial effect on weight in patients with endogenous CS.
Trial Registration: NCT00569582 (SEISMIC); NCT00936741 (Long-Term Extension).
Keywords: Cushing’s syndrome, Korlym, Long-term, Mifepristone, Obesity, SEISMIC, Weight loss* Correspondence: hfein@lifebridgehealth.org
1Johns Hopkins University School of Medicine and Sinai Hospital of
Baltimore, 2435 W. Belvedere Avenue, Baltimore, MD 21215, USA
Full list of author information is available at the end of the article
© 2015 Fein et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Fein et al. BMC Endocrine Disorders  (2015) 15:63 Page 2 of 7Background
Endogenous Cushing’s syndrome (CS), a complex meta-
bolic disorder resulting from prolonged exposure to ele-
vated cortisol, is associated with substantial morbidity
and mortality, particularly in relation to cardiovascular
events [1–4]. Obesity is a prominent feature of CS, with
70 to 80 % of patients characterized as either overweight
or obese [5–7]. Abdominal obesity contributes to insulin
resistance, metabolic abnormalities, and cardiovascular risk
in CS patients [6, 8, 9]. Although the mortality risk may
decrease once remission of hypercortisolism is achieved,
overall mortality and cardiovascular risk remain elevated
in these patients when compared with control populations
[4, 10]. Surgical resection of an adrenocorticotropic hor-
mone (ACTH)- or cortisol-secreting tumor, which is the
first-line treatment, often results in decreased body weight
during early remission [11–13]. However, recent studies
have shown that body weight can increase after initial im-
provement even if postoperative biochemical cure occurs
[7, 8, 14, 15], which may be a contributing factor in the in-
creased cardiovascular risk seen even where surgery was
successful.
In patients with recurrent or persistent hypercortisolism,
however—ie, in those for whom remission fails—mortality
is increased compared with control populations (standard-
ized mortality ratios 1.7–4.8) [3, 16, 17]. Given that long-
term recurrence of hypercortisolism after initial surgical
success following transsphenoidal pituitary surgery in
patients with Cushing’s disease (CD) has been re-
ported in up to 66 % of patients followed postopera-
tively for a mean duration of 14 years (range 1–37 years)
[11, 18–22], recurrent disease is a major concern. Second-
ary treatment options for patients with recurrent or per-
sistent endogenous CS, which may include pharmacologic
therapy, are thus often utilized. Data on the long-term
metabolic profiles of patients following pharmacologic
treatments are needed.
Mifepristone (KorlymW, Corcept Therapeutics, Menlo
Park, CA), a glucocorticoid receptor antagonist, was as-
sociated with significant improvements in hyperglycemia
in the 24-week SEISMIC (Study of the Efficacy and
Safety of Mifepristone in the Treatment of Endogenous
Cushing’s Syndrome) trial; 15/25 (60 %) had a ≥25 %
reduction in area under the curve for glucose and 21/40
(52.5 %) had either a ≥5 mmHg reduction in diastolic
blood pressure or reduction in antihypertensive medica-
tions [23]. A significant reduction in mean body weight
in patients with CS was also noted during the study. Pa-
tients who completed the SEISMIC study could elect to
enroll in a long-term safety extension (LTE) study. This
report presents follow-up data examining the persistent
effects of mifepristone on weight parameters in patients
from the SEISMIC study who subsequently entered the
LTE study.Methods
Details of the study design and patient population of
SEISMIC have been previously published [23]. SEISMIC
was a 24-week, open-label, multicenter study of mife-
pristone administered as a once-daily oral dose to adults
with confirmed endogenous CS who had type 2 diabetes
mellitus, impaired glucose tolerance, or a diagnosis of
hypertension [23] and had failed or were not candidates
for surgery. Mifepristone was started at a dose of 300 mg/
day, with titration to a maximum of 1200 mg/day based
on investigator clinical discretion. At the end of SEISMIC,
patients underwent a 6-week off-drug safety evaluation
period. Of the 34 patients who completed SEISMIC, 30
elected to enroll in the LTE study. The starting dose in the
LTE was the same as the final dose in SEISMIC, with fur-
ther dose titration at the discretion of the treating clinical
investigators. The study designs were approved by the
Western Institutional Review Board (Puyallup, WA)
and an institutional review board at each study center
[23]. Written informed consent was obtained from all
patients for both studies. Patients were free to discon-
tinue from the studies at any time.
This analysis reviews weight assessments taken at
baseline and week 24 of SEISMIC as well as at months
6, 12, 18, 24, and final visit (each patient’s last observation)
of the LTE study. Waist circumference and body com-
position were assessed in SEISMIC, but not the LTE.
Safety was assessed throughout the SEISMIC and exten-
sion studies via adverse events (AEs), vital signs, physical
exams, and clinical laboratory tests.
Statistical analysis
All numerically continuous data are presented as mean ±
SD unless otherwise specified. The percentage change
in body weight from baseline was evaluated across time
points using a mixed-model repeated-measures analysis
of variance. No imputations for missing data were per-
formed. Weight loss was evaluated descriptively using a
categorical loss of at least 5 % of the patient’s body
weight. A Kaplan-Meier plot was constructed based on the
time to achieve weight loss of ≥5 % in SEISMIC and
throughout the LTE. A separate plot was constructed to
show time to achieve weight loss of ≥10 %. Time was right
censored for patients who did not complete the LTE.
Weight loss persistence was defined as a loss of at least 5 %
of body weight at week 24 of SEISMIC that was maintained
to the indicated study visits in the LTE trial. An additional
analysis evaluated weight loss of ≥10 % at week 24 of
SEISMIC that was maintained at this threshold to the in-
dicated study visits in the LTE trial. All P-values ≤0.05
were considered statistically significant and no Bonferroni
corrections for simultaneous multiple inferences were per-
formed. All analyses were performed using SAS version
9.2 software (SAS Institute, Cary, NC).
Table 1 Demographic and baseline characteristics of patients
with evaluable body weight enrolled in the LTE study






Black or African American 5 (17)
Age, y
Mean (SD) 44.7 (11.2)
Min, max 26, 71
Weight, kg
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Patients
Of the 30 CS patients enrolled in the LTE (Fig. 1), evalu-
able body weight data were available for 29 patients (20
women and 9 men; mean age, 44.7 ± 11.2 years) (Table 1),
who were treated with mifepristone at an average daily
dose of 758 ± 290 mg. Twenty-six patients had CD and
three patients had ectopic ACTH. Baseline biochemical
status is reported in Table 2. Patients were treated in the
LTE for a median of 29.2 months (range 8.4–41.9 months),
and 25 patients received therapy for at least 2 years.
At baseline in the SEISMIC study, six patients (20.7 %)
were overweight (BMI 25–29) and 21 (72.4 %) were obese
(BMI ≥30); nine had a BMI ≥40. The mean waist circum-
ference was 122.4 ± 23.9 cm.Mean (SD) 105.4 (34.3)
Min, max 61.3, 198.7
BMI, kg/m2
Mean (SD) 37.7 (11.7)
Min, max 24.1, 66.4
BMI category, n (%)
< 25 2 (6.9)
25-29 6 (20.7)
≥ 30 21 (72.4)
≥ 40 9 (31)
BMI body mass index; LTE long-term extensionWeight loss and change in body composition during
SEISMIC and LTE
Among the 29 patients included in this analysis, mean
waist circumference decreased by 9.3 cm in women and
8.3 cm in men from baseline to week 24 of SEISMIC.
Mean percent total body fat declined by 3.7 % in women
and 0.3 % in men, and percent trunk fat declined by
2.5 % in women and 1.2 % in men by week 24 of SEIS-
MIC. On the other hand, mean total lean body mass in-
creased by 3.9 % in women and 1.3 % in men by week
24 of SEISMIC. Percentage decreases in body weight
from baseline were significant at weeks 10–24 of
SEISMIC (all P < 0.0001) and at each assessment in the
LTE (all P < 0.0001) (Fig. 2). A 7.5 % decrease in weight
was observed from baseline to week 24 (P < 0.0001). At
the 24-week visit during SEISMIC, 62.1 % (18/29) of pa-
tients had lost ≥5 % of baseline body weight. An add-
itional analysis found 34.5 % (10/29) of patients lost ≥10 %
of baseline body weight at the end of SEISMIC.
By the end of the LTE, 86 % (25/29) achieved ≥5 %
weight loss, while 72 % (21/29) achieved ≥10 % weight
loss. The crude rate for the 10 % weight loss was lower
than the life-table estimate observed in the Kaplan-Meier






Excluded from analysis (n=5)
• Did not enroll into LTE (n=4)
• Death (n=1)
Fig. 1 Participant flow. LTE: long-term extensionin weight was observed from baseline to final visit in the
LTE (P = 0.0008) (Table 3).Persistence of weight loss from SEISMIC across LTE
Of the 18 patients who lost ≥5 % of body weight by the
end of the 24-week treatment period, 83.3 % (n = 15)
maintained ≥5 % weight loss at final visit in the LTE
study (Table 4). Twelve of the 18 patients lost additional
weight in the LTE (7 lost ≥5 %, 5 lost <5 %). The six pa-
tients with weight gain during the LTE still had an average
net loss of 3.23 % (1.9 ± 4.4 kg) when compared to baseline
in SEISMIC. Of the ten patients who lost ≥10 % of body
weight during SEISMIC, 80 % maintained that degree of
weight loss by the LTE final visit.Safety
All patients (n = 29) reported at least one AE during the
LTE; the most common AEs reported were nausea (52 %),
decreased blood potassium (48 %), fatigue (45 %), headache
(38 %), and endometrial thickening (35 %). Three patients
discontinued from the study because of AEs (n = 1
each: adrenal insufficiency, endometrial thickening,
endometrial disorder). During the LTE, the term “adrenal
insufficiency” was used to describe the events experienced
by five patients. Three of these events were associated
Table 2 Baseline biochemistry for patients with evaluable weight data enrolled in the LTE study
Variable, mean (SD) Cushing’s disease (n = 26) Ectopic ACTH (n = 3) Overall (n = 29)
ACTH, pg/mL 54.5 (33.6) 180.0 (158.0) 67.5 (65.6)
24 h UFC, μg/24 h 144.9 (153.2) 3158.4 (3625.3) 456.6 (1353.5)
Serum cortisol, μg/dL 21.1 (5.8) 44.5 (16.9) 23.5 (10.2)
Late-night salivary cortisol, μg/dL 0.31 (0.32) 2.5 (2.4) 0.56 (1.0)
ACTH adrenocorticotropic hormone; UFC urinary free cortisol; LTE long-term extension
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insufficiency” were effectively managed with interruption
of mifepristone and administration of dexamethasone in
four patients and interruption of mifepristone without
glucocorticoid supplementation in one patient. SevereFig. 2 Mean percent change in body weight from baseline in SEISMIC by v
were statistically significant from weeks 10–24 in the 24-week treatment pe
Diamonds =means; horizontal lines within boxes =medians; ends of boxes
not longer than 1.5 times the interquartile range (IQR); circles = values beyohypokalemia (serum potassium ≤2.5 mEq/L) was reported
in four patients, which resolved with treatment that in-
cluded potassium supplements and mineralocorticoid
antagonists. No patients discontinued from the LTE be-
cause of hypokalemia.isit in a SEISMIC and by month in b LTE. *The changes from baseline
riod and at each time point in the long-term extension (P < 0.0001).
= 25th/75th percentiles; “whiskers” = range of the min to the max but
nd the 1.5 IQR. LTE: long-term extension
Fig. 3 Kaplan-Meier plot for proportion of patients achieving ≥5 and ≥10 % weight loss in SEISMIC and the LTE. LTE: long-term extension
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In CS, hypercortisolism can promote cardiometabolic
abnormalities similar to that of metabolic syndrome, in-
cluding increased abdominal fat, hypertension, diabetes
mellitus, and hyperlipidemia [6, 8, 24, 25], which con-
tribute to the increased cardiovascular risk and mortality
in these patients [2–4]. Terzolo et al. recently examined
cardiovascular risk among patients with CS, followed at
least 12 months postoperatively [10]. Patients with persist-
ent disease following surgery (n = 24) continued to have
elevated rates of hypertension (79 %), diabetes (54 %),
central obesity (77 %), and elevated triglycerides (54 %)
after 12 months, with little change compared to rates at
diagnosis. Among patients in remission (n = 51), the rate
of hypertension decreased by 41 %, central obesity de-
creased by 37 %, diabetes decreased by 17 %, and elevated
triglycerides decreased by 16 % compared with diagnosis.
However, despite the improvements following resolution
of hypercortisolism, the rates of central obesity and el-
evated triglycerides remained significantly higher thanTable 3 Persistence of weight loss in SEISMIC and the LTE
SEISMIC
Variable Baseline (n = 29) Week 24 (n = 29)
Weight, kg
Mean ± SD 105.4 ± 34.3 97.2 ± 30.8
Change weight — −8.2 ± 9.3
% Change in weight — −7.5 ± 7.1
BMI, kg/m2
Mean ± SD 37.7 ± 11.7 34.7 ± 10.0
BMI category, n (%)
≥ 30 21 (72.4) 17 (58.6)
≥ 40 9 (31.0) 7 (24.1)
Final visit is defined as the last post-entry observation collected during the LTE stud
BMI body mass index; LTE long-term extensionthe control population (45 vs 13 %; P = 0.0002 and 25
vs 5 %; P = 0.005, respectively). Therefore, increased
emphasis is needed to address CS-related comorbidities,
including cardiovascular risk, before and after remission
of hypercortisolism is achieved, as noted in recent CS
guidelines [17]. However, long-term data will be needed
to determine if improvement in cardiovascular risk fac-
tors in patients with CS will lead to a further reduction
in mortality.
While cardiovascular risk was not formally assessed in
the 6-week SEISMIC trial, treatment with mifepristone
was shown to improve glucose parameters in patients
with CS that were refractory to other therapies and who
had associated type 2 diabetes mellitus, impaired glucose
tolerance, or hypertension [23, 26]. Walia et al. further
demonstrated that large improvements in glucose toler-
ance and insulin sensitivity occurred during the first
6 weeks of mifepristone treatment [26] and continued to
improve as beneficial changes in weight and waist cir-
cumference were attained at week 24. Our current studyLTE
Month 6 (n = 27) Month 18 (n = 25) Final visit (n = 29)
95.2 ± 32.2 96.6 ± 34.7 95.1 ± 32.9
−10.5 ± 12.3 −11.4 ± 18.7 −10.3 ± 16.3
−9.7 ± 9.7 −10.0 ± 14.4 −9.3 ± 13.4
34.3 ± 9.7 34.0 ± 9.7 33.7 ± 9.9
16 (59.3) 16 (64.0) 18 (62.1)
6 (22.2) 4 (16.0) 6 (20.7)
y
Table 4 Categorical weight loss in SEISMIC and persistence during the LTE study
Categorical weight loss in SEISMIC Time point in LTE study Weight loss persistencea, n (%)
≥5 % weight loss (n = 18)b Month 6 14 (82.4)
Final visitc 15 (83.3)
≥10 % weight loss (n = 10)b Month 6 8 (80)
Final visitc 8 (80)
aPersistence is defined as maintenance of the weight loss threshold in SEISMIC to LTE assessment time points. bOne subject was excluded from this analysis
because the only post-baseline weight was assessed on the day of death, which occurred in the hospital in relation to a serious adverse event deemed not related
to study drug by the investigator. cFinal visit is defined as the last post-entry observation collected during the LTE study
LTE long-term extension
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can persist for up to 3.5 years of mifepristone treatment.
A weight loss of 5–10 % has been shown to reduce
cardiovascular risk factors in other at-risk populations
[27, 28]. For example, a randomized, multicenter trial
of obese and overweight patients with type 2 diabetes
found that a weight loss of 5 to <10 % after 1 year of
intensive lifestyle intervention was associated with a
statistically significant improvement in cardiovascular
risk factors including reductions in glycated hemoglobin
(A1c) and blood pressure [27].
Long-term therapy with mifepristone in patients with
CS was associated with an AE profile comparable to that
reported in the 24-week SEISMIC study [23]. There
were five reported cases of “adrenal insufficiency” during
the LTE, and all cases resolved with temporary drug
interruption with or without supplemental glucocorticoid
administration. Yuen et al. [29] recently described how
symptoms of “excessive glucocorticoid receptor antag-
onism” associated with mifepristone can resemble some
symptoms of adrenal insufficiency (eg, nausea, fatigue,
vomiting, and low appetite). However, serious symptoms
of adrenal crisis, such as hypotension or hyperkalemia, are
unlikely to occur due to the rise in cortisol levels and
subsequent activation of the mineralocorticoid receptors
during mifepristone therapy. If clinical signs or symptoms
of excessive glucocorticoid receptor antagonism are sus-
pected, therapy with mifepristone should be discontinued
temporarily, and in some cases, administration of supple-
mental glucocorticoids may be useful. Treatment can be
resumed at a lower dose once signs and symptoms of ex-
cessive glucocorticoid receptor antagonism are resolved.
This follow-up analysis of clinical trial data contributes
useful information on the long-term use of mifepristone
and weight loss in patients with CS. Other cardiometabolic
parameters, such as glycemic control, waist circumference,
and blood pressure, were not routinely assessed during the
LTE, nor did this study control for patient-specific factors
such as diet, physical activity, or other lifestyle modifica-
tions. Likewise, the influence of disease etiology on weight
outcomes was not examined because of the limited number
of patients that enrolled in the LTE with diagnoses other
than CD. Additional studies in patients with CS to assesslong term metabolic and cardiovascular benefits associated
with sustained weight loss from cortisol blockade with
mifepristone are warranted. It remains to be determined
whether sustained improvement in cardiovascular risk fac-
tors will translate to reduced mortality in patients with CS.
Conclusion
A follow-up analysis of clinical trial data found clinically
meaningful weight loss (≥5 % of body weight) achieved
during short-term mifepristone use was sustained in ap-
proximately 80 % of patients with CS who were treated
with mifepristone for up to 3.5 years. No new safety signals
were detected with long-term mifepristone use.
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